MECOM and acute lymphoblastic leukemia: The data set by Hogan et al.11 shows that in de novo ALL that subsequently relapses EVI1 expression has a significantly wider range compared with the de novo ALL cases that are not selected for subsequent relapse in the other studies (P<0.01).